Equine practitioners may still take the backseat to food animal practitioners in the debate over antimicrobial resistance, but their input may help sustain prudent use of controversial drugs for all species.
The notepad on Dr. Bill Rood's desk sums up the work ethic of a hospital whose clientele ranges from the Queen of England to Arab sheikhs. It reads, "Teamwork is the fuel that allows common people to produce uncommon results."
Treatment of painful conditions in horses has relied largely on nonsteroidal anti-inflammatory drugs (NSAIDs) for much of the last 25 years. For example, flunixin meglumine (Banamine®) and phenylbutazone (Butazolidin®) have dominated the market for treatment of colic and lameness respectively. However, it is becoming increasingly clear that these drugs also have some side effects, most notably gastrointestinal ulceration.
In May, the University of Kentucky (UK) released preliminary test results suggesting the eastern tent caterpillar and its waste remain chiefly responsible for increased foal losses in 2001, but the picture is "far from fully developed."